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Expression of p16 protein, intragenic mutations of CDKN2A and hypermethylation
of CDKN2A promoter region in 41 sporadic primary uveal melanomas were studied.
There were 2 cases of spindle cell B histological type, 11 of A + B and 28 of mixed type.
All melanomas infiltrated sclera but in 28 cases infiltration was superficial while in 13
profound. In 7 cases the tumor infiltrated the optic nerve. Expression of p16 was stud-
ied by immunohistochemistry and recorded by assessment of the proportion of posi-
tive tumor cells and staining intensity. Results were expressed as staining index (IRS).
Intragenic mutations were studied by PCR-SSCP followed by sequencing, while
hypermethylation of the promoter region by CpG methylation assay. In 15% of cases
less than 10% of melanoma cells were p16 positive, in 70% of cases less than 50% of
cells, while in 7% more than 80% of cells stained for p16 (mean IRS for all cases was
4.87  2.43). In B type the IRS was 8.5  0.7, in A + B type 6.0  2.1 and in the mixed
type 4.17  2.43 (differences statistically significant). In melanomas profoundly infil-
trating sclera mean IRS was 4.16, while in those infiltrating optic nerve 3.71 (statisti-
cally not significant). Analysis of the intragenic mutations revealed in two patients a
GAC/GAT substitution in codon 84 — a silent mutation. No hypermethylation of the
CpG island of the p16 promoter region was found. In conclusion, we found that the de-
gree of p16 expression is related to the histological type of tumor but not to the
histological indicators of tumor invasiveness and that intragenic mutations and pro-
moter hypermethylation are not major mechanisms of p16 inactivation in sporadic
uveal melanoma.
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Thirteen percent of primary melanomas de-
velop within an eye and the eye is, next to
skin, the most frequent site of melanoma lo-
calization (30–79%). Despite the fact that both
tumors arise from melanocytes their biology
differs substantially. Some differences in the
clinical course of the disease might be as-
signed to anatomic localization or immune re-
sponse to the primary tumor. Nevertheless,
the kinetics of disease development or signifi-
cant variation of metastases responsiveness
to chemical agents could also be due to other
factors such as genetic alterations. Similarly
to skin melanoma various stages of the eye
melanoma progression may be distinguished
(Garner & Klintworth, 1994). The progression
of skin melanoma is associated with inactiva-
tion of a number of tumor suppressor genes
(Fountain et al., 1990). These processes, how-
ever, have not been extensively studied in eye
melanoma so far. Merbs & Sidransky (1999)
reported an analysis of a tumor suppressor
gene an inhibitor of cyclin-dependent kinase
(CDK) 4 and 6 — p16 Ink4a (CDKN2A/MTS-1)
locus — in 33 primary sporadic uveal melano-
mas for loss of heterozygosity (LOH) of chro-
mosome 9p21 and examined the mechanisms
of p16 inactivation in these tumors.
The CDKN2A gene was mapped to the 9p21
chromosome region. It encodes the cyclin de-
pendent kinase inhibitor p16 and p14 ARF, an
alternatively spliced form (Kamijo et al.,
1997). Both proteins act as negative cell cycle
regulators. Mutations and other genetic alter-
nations in CDKN2A were found in cell lines
derived from skin melanoma but role of these
changes in initiation and progression of skin
melanoma is still under debate. Studies of ge-
netic changes in CDKN2A and the expression
level of p16 protein suggest that loss of
heterozygosity and protein expression play
important roles in the progression of mela-
noma (Keller-Melchior et al., 1998) and are
characteristic for the advanced stages of this
type of tumor (Cairns et al., 1995).
In this work p16 expression was examined in
various histological types of uveal melanoma
and in cases displaying signs of invasiveness
such as profound sclera or optic nerve infiltra-
tion. In addition we analyzed p16 intragenic
mutations and hypermethylation of the pro-
moter region as possible mechanisms of inac-
tivation of this gene. Studies were carried out
in fresh non cultured cells and in paraffin em-
bedded tissues.
MATERIALS AND METHODS
Patients. Enucleation due to eye melanoma
was performed in 41 patients (mean age 56
years; range 21–77). In 37 patients the mela-
noma was localized within the uvea while in 4
within the uvea and ciliary body. Following
enucleation tumor tissue was divided into two
parts. One was fixed in formalin for histo-
logical diagnosis and immunohistochemistry,
and the other was frozen in liquid nitrogen for
further DNA isolation. Histological diagnosis
of uveal melanoma assessed for cell type using
the modified Callender system (McLean et al.,
1983) revealed: 2 cases of spindle B, 11 cases
of spindle A + B, and 28 of mixed type. All mel-
anomas infiltrated sclera, however, in 28
cases infiltration was superficial while in 13
profound. In 7 cases tumors infiltrated the op-
tic nerve.
Immunohistochemistry. Expression of p16
proteins in melanoma tissue was analyzed
immunohistochemically by the labelled strep-
tavidin/biotin method on formalin-fixed, par-
affin embedded tissues. Sections of 4 m were
dewaxed in xylene, and rehydrated through
descending graded alcohols to phosphate-buf-
fered saline, pH 7.4 (NaCl/Pi). Due to a very
high melanine content slides were incubated
for 30 min in 0.25% aqueous potassium per-
manganate solution, washed in tap water and
soaked in 5% aqueous solution of oxalic acid
for 2–5 min (until sections become clear).
Then, following blocking of endogenous
peroxidase activity with 1% H2O2 (30 min)
and non-specific antibody binding with 1% bo-
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vine albumin in NaCl/Pi for 30 min, sections
were incubated with primary antibodies. Incu-
bation was carried out with polyclonal rabbit
anti-human p16 antibodies (Santa Cruz Bio-
technology, CA, U.S.A.) in 1:1500 dilution in
NaCl/Pi overnight at 4C followed by 1 h incu-
bation at room temperature. Sections were
subsequently incubated with prediluted
biotinylated link antibody (DAKO LSAB 2
Kit, Dako Corp. CA, U.S.A.) for 30 min fol-
lowed by streptavidin-horseradish peroxidase
conjugate one (DAKO LSAB 2 Kit, Dako Corp.
CA, U.S.A.) for 30 min. After washing,
peroxidase activity was detected using
3,3-diaminobenzidine as chromogen with
H2O2 as substrate. The sections were counter
stained with haematoxylin, dehydrated,
cleared in xylene and mounted.
For recording of p16 immunohistochemical
staining a semi-quantitative and subjective
grading, considering both the proportion of tu-
mor cells showing positive reaction and inten-
sity of staining was used. The proportion of
stained cells (PP) was graded as: 0 — no tumor
cells positive, 1 — positive staining in < 10% of
tumor cells, 2 — positive staining in 10–50% of
tumor cells, 3 — positive staining in 50–80% of
tumor cells, 4 — positive staining in > 80% tu-
mor cells. Staining intensity (SI) was graded
as: 0 — no staining, 1 — weak staining, 2 — mod-
erate staining, 3 — strong staining. Staining in-
dex (IRS): PP times SI (range: 0–12).
DNA extraction. Genomic DNA was ex-
tracted from melanoma tissue samples previ-
ously frozen in liquid nitrogen. Samples were
homogenized and DNA was prepared using a
standard method with proteinase K, several
phenol/chloroform extractions followed by
ethanol precipitation. In samples containing a
high amount of melanin DNA was purified us-
ing Wizard purification resin (Promega, WI,
U.S.A.) or spin columns (Qiagen, CA, U.S.A.)
according to the manufacturer’s instructions.
PCR-SSCP analysis. For analysis of point
mutations in the p16 gene the PCR-SSCP
method was used with the following pairs of
primers: 1/16F: GGGAGCAGCATGGAGC-
CG; 1/16R: AGTCGCCCGCCATCCCCT; 2A/
16F: AGCTTCCTTTCCGTCATG; 2A/16R:
GCAGCACCACCAGCGTG; 2B/16F: AGC-
CCAACTGCGCCGAC; 2B/16R: CCAGGTC-
CACCGGCAGA; 2C/16F: TGGACGTGCGC-
GATGC; 2C/16R: GGAAGCTCTCAGGGTAC-
AAATTC; 3/16F: CCGGTAGGGACGGCAA-
GAGA; 3/16R: CTGTAGGACCCTCGGTGA-
CTGATGA. The primers used for PCR-SSCP
were end labelled by [-32P]ATP (3000 Ci/
mmol, Amersham). PCR was carried out in a
total volume of 5 l with the following re-
agents: 1 x PCR buffer, 1.5 mM MgCl2, dNTPs
0.2 mM each, primers 1 M each, 6% Me2SO,
Taq Pol. 2.5U/100 l (Promega WI, U.S.A.)
and 50 ng of genomic DNA. The amplification
program consisted of 35 cycles: 94C/5’;
94C/30”, 55C/30”, 72C/30”; 72C/5’ for
p16 fragments 2A, 2B and 2C; 94C/5’;
94C/30”, 58C/30”, 72C/30”; 72C/5’ for
fragments including exons 1 and 3. The PCR
products were mixed with 1/9 volume of
formamide dye mixture, heated at 95C/5’
and loaded onto the gel. SSCP analysis was
carried out in 5% polyacrylamide gel with 10%
glycerol, at room temperature at 15 W. The
gel was transferred into Whatman 3MM pa-
per, dried and autoradiographed.
Sequencing. Bands showing mobility shift
were cut from the gel, eluted into water and
reamplified. PCR products were subjected to
electrophoresis in 1.5% agarose gels, cut out
and purified using gel extraction kit (Qiagen,
CA, U.S.A.). The purified PCR products
served as template in the cycle sequencing
procedure using the fmol DNA sequencing
System (Promega, WI, U.S.A.). End labelled
amplimers were used as sequencing primers.
Products of sequencing reactions were run in
a gel containing 7.5 M urea, dried and auto-
radiographed.
Methylation assay. DNA (5 g) was modi-
fied using 3 M sodium bisulfite with 10 mM
hydroquinone according to the previously de-
scribed method (Herman et al., 1996) and CpG
Methylations Assay (Oncor, MD, U.S.A.).
Modified DNAs were purified by Wizard puri-
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fication resin (Promega, WI, U.S.A.) and
eluted into water. The reaction was termi-
nated by NaOH treatment, followed by etha-
nol precipitation. DNA was resuspended in
water and used in PCR reaction with primers
described previously (Herman et al., 1996).
PCR reactions were performed in 10 l vol-
ume with Gold Taq Polymerase (Perkin
Elmer, NJ, U.S.A.) and consisted of the follow-
ing steps: 95C/10; 95C/45, 60C/45,
72C/60  35 and 72C/5 of terminal elon-
gation. PCR products were analyzed by elec-
trophoresis in a 2% agarose gel.
Statistics. Statistical analysis was carried
out using Student’s t-test 2 and Spearman
rank correlation tests.
RESULTS
Immunohistochemical evaluation of p16 in
uveal melanoma tissue
Most of p16 positive melanoma cells showed
staining only in nuclei. In a few cases staining
in both nuclei and the cytoplasm was observed
(Fig. 1). In one case no p16 staining was de-
tected (PP — 0). In 6 cases < 10% positive cells
(PP — 1), in 22 cases 10–50% positive cells (PP
— 2), in 9 cases 50–80% positive cells (PP — 3)
and in 3 cases > 80% positive cells (PP — 4)
were found. Staining index negative or very
weak (IRS  2) was demonstrated by 9 cases
(23%), very strong index (IRS 8–9) 7 cases
(17%) and intermediate (IRS 3 — 6) 25 cases
(61%). Mean IRS for all cases was 4.87 ± 2.43.
In spindle cell type B the mean p16 IRS value
was 8.5 ± 0.7, in A + B type 6.0 ± 2.1 and in the
mixed type 4.17 ± 2.24. Statistically signifi-
cant differences between all histological types
(P < 0.002–0.006) with the exception between
type B and type A + B were found.
In uveal melanomas profoundly infiltrating
sclera the mean p16 IRS value was 4.16 ±
1.85, while in those infiltrating optic nerve
3.71 ±1.88. No statistical differences (using
Student’s t-test) between melanomas superfi-
cially and profoundly infiltrating sclera (P <
0.09) or optic nerve (P < 0.76) were found (Ta-
ble 1).
PCR-SSCP analysis
In two patients a mobility shift different in a
fragment of exon 2 of the p16 gene was ob-
served. Sequencing analysis of these bands re-
vealed a substitution in codon 84 GAC/GAT
(Asp/Asp — silent mutation) (Fig. 2).
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Figure 1. Immunohistochemical staining of p16 protein in uveal melanoma.
A, control — no p16 antibody. B, nuclear and nuclear/cytoplasmic localization of p16 protein.
Methylation analysis
The CpG islands of the p16 promoter regions
demonstrated PCR products only with prim-
ers designed for unmethylated DNA. We ob-
served no PCR products in the reaction with
primers for methylated DNA with the excep-
tion of control DNA used as a control of modi-
fication and PCR correctness (Fig. 3).
DISCUSSION
There are two major findings of the study: (i)
the degree of p16 expression is statistically re-
lated to histological type of the primary spo-
radic melanoma but is not a histological indi-
cator of tumor invasiveness, (ii) intragenic
mutations or promoter hypermethylation are
not major mechanisms of p16 inactivation in
sporadic primary uveal melanoma.
The p16 protein immunostain localizes dom-
inantly to the nucleus, while cytoplasmic
colocalization might be also seen (Hara et al.,
1996). In uveal melanoma cells we observed
p16 nuclear immunostaining and in a few
cases cytoplasm co-immunolocalization. A sig-
nificant heterogeneity in the percentage of
p16 positive cells and staining intensity was
observed. Only in one case there were no posi-
tive cells present. About 15% of cases demon-
strated p16 expression in less than 10% of
cells, while about 70% of cases in less than
50%. Only 7% of uveal melanomas showed
more than 80% of cells positively stained for
p16. In order to evaluate p16 expression more
precisely the staining index (IRS) which is
based on number of positive cells and staining
intensity was adopted (Remmele & Stegner,
1987). Statistically significant differences of
p16 IRS were observed between histological
types of the tumor. The lowest IRS was found
in the mixed type uveal melanoma. Lower IRS
than in the whole material studied was also
found in tumors displaying signs of inva-
siveness. However, probably due to the small
number of cases in the analysis, the differ-
ences were statistically not significant. There
is only one report on p16 expression in uveal
melanoma so far (Coupland et al., 1998). In
these studies p16 showed both nuclear and
cytoplasmatic staining. Only in 45% of cases
positive p16 staining was observed. The
amount of positively stained cells varied be-
tween 5–25% (mean 12%) of tumor cells. No
correlation between histological type and p16
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Figure 2. Example of PCR-SSCP analysis of p16 gene — fragment of exon 2.
The arrows indicate lanes with mutated bands.
Table 1. p16 IRS index in different histological
type of uveal melanoma
p16 IRS B A+B mix
0–2 0 (0%) 1 (9%) 8 (29%)
3–6 0 (0%) 7 (69%) 18 (64%)
7–9 2 (100%) 3 (27%) 2 (7%)
expression was seen. Those results signifi-
cantly differ from the data presented in this
study. One of the possible reasons of the dis-
crepancy might by the difference in the anti-
body used. Coupland et al. (1998) employed
monoclonal antibodies, while in our studies
polyclonal antibodies were used. In skin mela-
noma Reed et al. (1995) demonstrated that
p16 retains its expression in melanoma in situ
and in the majority of primary melanomas,
while 52% of primary invasive tumors and
72% of metastatic lesions demonstrate partial
or complete loss of p16 expression. Similar re-
sults were obtained by Grover et al. (1998)
who showed high p16 expression in benign
melanocytic neavi (96% positive) and signifi-
cant reduction in primary melanomas (31%
negative) and metastatic lesions (63% nega-
tive). Others correlated loss of p16 expression
with tumor cell proliferation and the invasive
stage of melanoma (Sparrow et al., 1998).
Those data suggest that loss of p16 expression
is not necessary for tumor initiation in malig-
nant skin melanoma but is potentially more
related to invasiveness or the ability to
metastasize. Finally, an association was found
between absent or very weak p16 staining and
markedly decreased survival rates (Strume &
Akslen, 1997). As already pointed out metas-
tases of uveal melanoma were not analyzed in
this study. However, the number of negative
or weakly positive p16 primary sporadic uveal
melanomas was significantly lower than the
corresponding number of primary skin mela-
nomas suggesting some differences in genetic
mechanisms of progression between these tu-
mors.
There is a number of possible mechanisms of
p16 inactivation in melanoma and uveal mela-
noma. They include homozygous deletion
(Peng et al., 1995), LOH (Flores et al., 1996),
intragenic mutations (Smith-Sorensen &
Hoving, 1996), hypermethylation of CpG is-
lands of promoter region (Herman et al.,
1995) and microsatellite instability (Mat-
sumura et al., 1998). In this study we analyzed
two of the possible mechanisms listed above,
namely intragenic mutations and methylation
of CpG islands in promoter regions. Muta-
tions in the p16 gene are found in melanoma
cell lines (Liu et al., 1995). Germinal muta-
tions in this gene have also been reported in
familial cutaneous melanoma (Holuska &
Hodi, 1998). Somatic mutations are present
but with lower frequency. Since small dele-
tions and nonsense mutations are found in
the p16 gene which often leads to the loss of
the p16 protein product, we have analyzed
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Figure 3. Results of methylation analysis of CpG islands in the promoter region of the p16 gene on 1.5%
agarose gel.
Primer sets were designed as unmethylated (u) and methylated (m). In lanes marked M, DNA size marker (left:
GeneRuler 100 bp DNA ladder, right: PCR Marker Promega); lanes 1 and 2, products of MSP analysis on control
DNA samples; lanes 3–11, examples of MSP analysis on DNA from cancer cells.
p16 gene for the presence of such small ge-
netic changes using the PCR-SSCP. In the p16
gene the substitution C/T was found in two
cases, but this mutation had no effect on the
amino-acid residue. This silent mutation
within p16 were found frequently in other
types of cancer patients in Poland, such as
lung cancer (unpublished). Accordingly, we
regard it as the most frequent p16 polymor-
phism in this country. Others did not find mu-
tations in the p16 gene in primary sporadic
uveal melanoma either (Merbs & Sidranski,
1999).
Next we analyzed possible silencing of p16
gene by hypermethylation of CpG islands in
promoter regions — a second possible way of
p16 gene inactivation in melanoma. As a re-
sult we did not find methylation in the pro-
moter region of this gene. Merbs & Sidransky
(1999) observed hypermethylation of p16 pro-
moter region in only 2 of 33 primary uveal
melanomas studied. Accordingly, the above
results and our study suggest that hyper-
methylation of the promoter region does not
play a major role in p16 inactivation in this
type of tumor.
In recent reports LOH at 9p21 and 9p21-22
were found by means of microsatellite marker
in 24% (Merbs & Sidranski, 1999) and 32% of
sporadic primary uveal melanoma cases, re-
spectively (Ohta et al., 1996). Similarly, LOH
at 9p21 is frequently found in sporadic skin
melanomas. Furthermore, studies of LOH at
9p21 in primary skin melanoma and mela-
noma metastases revealed that LOH appeared
in the later stages of melanoma development
(Morita et al., 1998). It is, however, interest-
ing that in the studies where LOH was re-
ported very limited or no point mutations
were found (Ruiz et al., 1998). Moreover, in
the study of LOH at 9p21 in uveal melanoma
expression of p16 protein was not analyzed. It
is, therefore difficult to speculate on the rela-
tionship between LOH at 9p21 and p16 ex-
pression. On the other hand, a study on spo-
radic melanoma demonstrated that partial or
complete loss of p16 expression is frequently
associated with 9p21 LOH (Funk et al., 1998).
Also homozygous p16 losses have been re-
ported in skin melanomas (Wagner et al.,
1998).
The differences in p16 expression could be
also caused by other mechanisms. Examples
include selective loss of the gene locus, failure
of other steps in protein biosynthesis or
changes in other genes such as Rb, which was
reported to be frequently phosphorylated at
serine 807 and serine 811, and cyclin D1 was
expressed in many of the tumors. Phospho-
rylation of the COOH terminal region is also a
possible mechanism of Rb inactivation in
uveal melanomas (Brantly & Harbour, 2000).
Also other inhibitors of the cell cycle machin-
ery such as p21, p27, p53 and Ki67 (Mib-1)
were studied in uveal melanoma, and an at-
tempt was made to correlate with clinico-
pathologic parameters. The results suggested,
that only p21 and p27 may be involved in
tumorgenesis in choroidal melanoma (Brantly
& Harbour, 2000). Undoubtedly, studies of
the more advanced stages of uveal melanoma
cases might help to resolve the genetic cas-
cade involved in uveal melanoma progression
and appreciate the role of the p16 gene in this
type of cancer.
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